RETRACTED: Crystal structure of a complement control protein that regulates both pathways of complement activation and binds heparan sulfate proteoglycans
- PMID: 11207370
- DOI: 10.1016/s0092-8674(01)00214-8
RETRACTED: Crystal structure of a complement control protein that regulates both pathways of complement activation and binds heparan sulfate proteoglycans
Retraction in
- 10.1016/s0092-8674(01)00214-8
Abstract
This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/our-business/policies/article-withdrawal). This article has been retracted at the request of request of the editors. Cell is retracting this paper reporting structures of a poxvirus protein, VCP, that inhibits the complement system. The paper presents a structural model derived from two crystal forms of the protein (PDB: 1G40 and 1G44) that defines an interaction surface implicated in inhibition of complement C3 proteins and visualizes heparin binding sites. We were contacted by the University of Alabama, Birmingham (UAB), the corresponding author's institution, with a report detailing concerns about the veracity of the structures and recommending that the structures be retracted from the Protein Data Bank. We then conducted an assessment with input from experts in the field who found that the structures as presented in the paper were not consistent with available data, including spatial packing and structure (B) factors. These findings were consistent with issues contained in the UAB report. A subsequent investigation by the Department of Health and Human Services Office of Research Integrity (https://www.federalregister.gov/documents/2018/04/16/2018-07782/findings-of-research-misconduct) has concluded that the corresponding author, Krishna H.M. Murthy, engaged in research misconduct and that the structures were falsified and/or fabricated. Given the results of our own assessment and the institutional investigations, the most appropriate course of action is to retract the paper. Co-authors Nick Mullin, Paul N. Barlow, and Craig M. Ogata support this retraction.
Comment in
-
Findings of Research Misconduct.Fed Regist. 2018 Apr 16;83(73):16370-16371. Fed Regist. 2018. PMID: 30407470 Free PMC article. No abstract available.
Similar articles
-
Vaccinia complement control protein: multi-functional protein and a potential wonder drug.J Biosci. 2003 Apr;28(3):265-71. doi: 10.1007/BF02970146. J Biosci. 2003. PMID: 12734405 Review.
-
Conserved surface-exposed K/R-X-K/R motifs and net positive charge on poxvirus complement control proteins serve as putative heparin binding sites and contribute to inhibition of molecular interactions with human endothelial cells: a novel mechanism for evasion of host defense.J Virol. 2000 Jun;74(12):5659-66. doi: 10.1128/jvi.74.12.5659-5666.2000. J Virol. 2000. PMID: 10823874 Free PMC article.
-
RETRACTED: In vitro and in vivo evaluation of degradation, toxicity, biodistribution, and clearance of silica nanoparticles as a function of size, porosity, density, and composition.J Control Release. 2019 Oct;311-312:1-15. doi: 10.1016/j.jconrel.2019.08.028. Epub 2019 Aug 26. J Control Release. 2019. Retraction in: J Control Release. 2023 Mar;355:622-623. doi: 10.1016/j.jconrel.2023.02.018. PMID: 31465825 Free PMC article. Retracted.
-
Vaccinia virus complement control protein is monomeric, and retains structural and functional integrity after exposure to adverse conditions.Biochim Biophys Acta. 2002 Jul 29;1598(1-2):55-64. doi: 10.1016/s0167-4838(02)00339-4. Biochim Biophys Acta. 2002. PMID: 12147344
-
RETRACTED: New findings for dentin sialophosphoprotein studies: Applications of purified odontoblast-like cells derived from stem cells.J Oral Biosci. 2016 Nov;58(4):128-133. doi: 10.1016/j.job.2016.07.001. Epub 2016 Jul 13. J Oral Biosci. 2016. Retraction in: J Oral Biosci. 2020 Sep;62(3):296. doi: 10.1016/j.job.2020.06.005. PMID: 32512681 Retracted.
Cited by
-
Variola virus immune evasion design: expression of a highly efficient inhibitor of human complement.Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8808-13. doi: 10.1073/pnas.112220499. Epub 2002 May 28. Proc Natl Acad Sci U S A. 2002. PMID: 12034872 Free PMC article.
-
Solution structure of a functionally active fragment of decay-accelerating factor.Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4718-23. doi: 10.1073/pnas.0730844100. Epub 2003 Apr 2. Proc Natl Acad Sci U S A. 2003. PMID: 12672958 Free PMC article.
-
The structure of C2b, a fragment of complement component C2 produced during C3 convertase formation.Acta Crystallogr D Biol Crystallogr. 2009 Mar;65(Pt 3):266-74. doi: 10.1107/S0907444909000389. Epub 2009 Feb 20. Acta Crystallogr D Biol Crystallogr. 2009. PMID: 19237749 Free PMC article.
-
Vaccinia complement control protein: multi-functional protein and a potential wonder drug.J Biosci. 2003 Apr;28(3):265-71. doi: 10.1007/BF02970146. J Biosci. 2003. PMID: 12734405 Review.
-
Viral-derived complement inhibitors: current status and potential role in immunomodulation.Exp Biol Med (Maywood). 2017 Feb;242(4):397-410. doi: 10.1177/1535370216675772. Epub 2016 Oct 26. Exp Biol Med (Maywood). 2017. PMID: 27798122 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous